Condition: Crohn's Disease · Sponsor: Jiangsu Topcel-KH Pharmaceutical Co., Ltd.
The purpose of this study is to evaluate the efficacy of human TH-SC01 cell injection for the treatment of perianal fistulas in Crohn's Disease over 24 weeks.
This description comes directly from the study's public registry record.
Jueyu Xia, Master · 025-52700103 · xiajueyu@topcelbio.com
Always discuss trial participation with your own doctor first.
| Jiangsu Topcel-KH Pharmaceutical Co., Ltd. | Nanjing, Jiangsu, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06925594